How to Value a Pharmacy in 2026

Having worked on dozens of pharmacy transactions over the past decade, I can tell you this: pharmacy valuation in 2026 looks nothing like it did five years ago. The independent pharmacy landscape has been reshaped by PBM reimbursement compression, major chain closures, and the explosive growth of specialty and compounding niches. If you're still thinking about your pharmacy's value in terms of a simple revenue multiple, you're almost certainly getting it wrong.

Our database tracks 237 pharmacy transactions, and the spread in multiples tells a dramatic story. The overall median sits at 10.67x EBITDA and 0.92x revenue, but those numbers mask enormous variation depending on what kind of pharmacy you operate, who your patients are, and what programs you participate in.

The Two Tiers of Pharmacy Valuation

In my experience, the pharmacy market has split into two distinct valuation tiers, and the gap between them is widening every year.

Tier 1: Standard retail/community pharmacies filling commercial and Medicare Part D prescriptions. These are the pharmacies getting squeezed hardest by PBMs. For businesses under $5M in enterprise value, we see multiples around 4.33x EBITDA and 0.45x revenue. In the $5-25M range, that improves to 6.59x EBITDA and 0.72x revenue. These are still viable businesses, but margins have compressed from 22-25% a decade ago to 18-20% today, and buyers price that trajectory in.

Tier 2: Specialty, compounding, long-term care, and 340B pharmacies. These command significantly higher multiples because they've found defensible niches with structural margin advantages. A specialty pharmacy with established limited distribution drug relationships and accreditations can trade at 2-3x the multiple of a comparable-revenue retail pharmacy. I've seen compounding pharmacies with strong physician referral networks sell for 8-10x EBITDA at the SMB level.

Why PBM Pressure Matters More Than You Think

Every pharmacy owner I talk to understands that PBMs are squeezing margins. But many underestimate how directly this hits their valuation. Buyers aren't just looking at your current margins — they're modeling what happens over the next 3-5 years as reimbursement rates continue to erode.

The math is brutal. If your pharmacy fills 300 prescriptions per day at an average reimbursement of $12 and your cost-to-fill is $10.50, you're making $1.50 per script, or $450 per day in gross margin on dispensing. A $0.50 reduction in average reimbursement — which is well within what PBMs have clawed back annually — wipes out a third of your dispensing margin. Sophisticated buyers model these scenarios, and they adjust their offers accordingly.

The pharmacies that maintain value are the ones that have diversified beyond dispensing. Front-end retail, clinical services (immunizations, point-of-care testing, medication therapy management), and specialty niches all contribute margin that isn't subject to PBM compression.

The 340B Premium

If your pharmacy participates in the 340B Drug Pricing Program — either as a covered entity or as a contract pharmacy for a covered entity — this is likely the single most valuable asset in your business. I've seen 340B eligibility add 30-50% to a pharmacy's valuation, and in some cases more.

The reason is straightforward: 340B allows covered entities to purchase outpatient drugs at significantly discounted prices (often 25-50% below wholesale) while collecting standard reimbursement from insurers. The spread is enormous, and it goes directly to the bottom line. A pharmacy generating $500K in annual 340B margin at an 8x multiple just added $4M to its enterprise value.

But buyers are also cautious. The 340B program faces ongoing regulatory scrutiny, and contract pharmacy arrangements have been challenged by manufacturers. Smart buyers will discount 340B income based on their assessment of program durability. If your 340B revenue is more than 40% of total gross profit, expect buyers to apply a risk adjustment.

Specialty and Compounding: Where the Premiums Are

Specialty pharmacy is the fastest-growing segment of pharmaceutical spending, and the valuations reflect it. Pharmacies with established specialty capabilities — meaning accreditations (URAC, ACHC), limited distribution drug access, patient management programs, and cold chain infrastructure — trade at substantial premiums.

What makes specialty pharmacies so valuable to acquirers:

• High barriers to entry: Accreditations take 12-18 months to obtain. Limited distribution agreements can take years to secure. A buyer can't replicate this quickly.
• Sticky patient relationships: Specialty patients are on chronic therapies and rarely switch pharmacies mid-treatment. Retention rates exceed 90% in well-run programs.
• Higher revenue per script: Average specialty script revenue is $3,000-$5,000 vs. $50-$75 for retail. Even at thinner margins, the absolute dollars are compelling.
• Recurring revenue dynamics: Patients refill monthly. This creates the kind of predictable recurring revenue that buyers pay up for.

Compounding pharmacies occupy a similar premium niche, though for different reasons. A compounding pharmacy with strong physician relationships, particularly in dermatology, hormone replacement, or pain management, has referral-based revenue that is genuinely difficult to replicate. The key metric buyers examine is physician referral concentration — if three doctors account for 60% of your compounding scripts, that's a concentration risk that will haircut your multiple.

Long-Term Care Pharmacy: The Contract Play

Long-term care (LTC) pharmacies serving nursing homes, assisted living facilities, and group homes have a unique valuation dynamic: the value is in the contracts. An LTC pharmacy with 15 facility contracts serving 2,000 beds has quantifiable, recurring revenue that a buyer can underwrite with confidence.

I've worked on LTC pharmacy deals where the contract portfolio was valued separately from the dispensing operation. The contracts themselves — assuming reasonable terms, 2+ years remaining, and good facility relationships — can be worth $500-$1,500 per bed served, on top of the pharmacy's operating value.

The risk factor that sophisticated buyers focus on is facility ownership consolidation. If a regional skilled nursing operator acquires three of your five largest facilities, they may consolidate pharmacy services to their preferred vendor. Contract terms and relationships matter enormously here.

The CVS/Walgreens Closure Opportunity

Between 2023 and 2026, CVS closed over 900 stores and Walgreens shuttered more than 1,200. Rite Aid went through bankruptcy. This retail pharmacy contraction has created a genuine opportunity for independent pharmacies in newly underserved markets.

If your pharmacy has absorbed prescription volume from chain closures, this is a compelling story for buyers. It demonstrates organic growth in a market where competition is retreating rather than advancing. I've seen pharmacies that picked up 50-100 scripts per day from chain closures receive premium offers because the acquirer views that volume as structurally sticky — those patients have already made the switch and have no chain alternative to go back to.

Document this growth carefully. Show the before-and-after script counts, identify which chains closed in your area, and quantify the incremental volume. This narrative matters to buyers.

What Drives Pharmacy Value Up — and Down

Based on the transactions I've analyzed, here are the factors that move the needle most in pharmacy valuations:

Value drivers:

• 340B program participation: The single biggest value enhancer for eligible pharmacies.
• Specialty/compounding accreditations: URAC, ACHC, and limited distribution access create durable competitive advantages.
• Script growth trend: Two years of consistent 5%+ script count growth signals a healthy, growing business.
• Diversified payer mix: No single PBM controlling more than 30% of your volume reduces reimbursement risk.
• Clinical services revenue: Immunizations, MTM, point-of-care testing — margin that bypasses PBM compression.

Value killers:

• Declining script count: Nothing scares a pharmacy buyer faster than shrinking volume. If scripts are declining, diagnose and fix it before going to market.
• Single-PBM concentration: If one PBM controls 50%+ of your reimbursement, you're one contract change away from a margin collapse.
• No pharmacist depth: If you're the only pharmacist and the business can't operate without you, buyers see massive owner dependency risk.
• DIR fee exposure: Direct and indirect remuneration fees are unpredictable and growing. Buyers want to see how you're managing and accounting for them.

Preparing Your Pharmacy for Sale

If you're thinking about selling in the next 2-3 years, here's what I tell every pharmacy owner:

Get your 340B house in order.If you're eligible and not participating, you're leaving significant value on the table. If you are participating, make sure your compliance documentation is bulletproof. Buyers will scrutinize 340B compliance more than any other aspect of your operation.

Build clinical services.Every immunization, MTM session, and point-of-care test you add is margin that doesn't flow through PBM reimbursement. Buyers love this diversification.

Document everything. Script counts by month, payer mix trends, gross margin by category, DIR fee history, facility contracts with terms and expiration dates. The more data you hand a buyer, the less uncertainty discount they apply. Review the current industry multiples to benchmark where your pharmacy falls.

Hire a second pharmacist. Even part-time coverage demonstrates that the business operates independently of you. This matters enormously for valuation, particularly at the SMB level where owner dependency is the number one value discount.

The Bottom Line

Pharmacy valuation in 2026 is a tale of two markets. Standard retail pharmacies face margin headwinds that compress multiples, while specialty, compounding, LTC, and 340B-eligible pharmacies command premiums that can be double or triple the baseline. The owners who position their pharmacies in the premium tier — through accreditations, program participation, clinical diversification, and contract development — will capture significantly more value at exit than those who rely solely on retail dispensing volume. The data across 237 transactions makes this unambiguous.